Beyond our core expertise in standard discovery and preclinical toxicology services, Frontier also specializes in studies involving drug candidates for the treatment of acute radiation syndrome (ARS), from demonstration of efficacy in representative animal models (rodents, rabbits, and non-human primates), to pivotal, GLP studies under FDA’s “Animal Rule”.